Cargando…

Ca(v)1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons

Dopamine midbrain neurons within the substantia nigra are particularly prone to degeneration in Parkinson’s disease. Their selective loss causes the major motor symptoms of Parkinson’s disease, but the causes for the high vulnerability of SN DA neurons, compared to neighbouring, more resistant ventr...

Descripción completa

Detalles Bibliográficos
Autores principales: Dragicevic, Elena, Poetschke, Christina, Duda, Johanna, Schlaudraff, Falk, Lammel, Stephan, Schiemann, Julia, Fauler, Michael, Hetzel, Andrea, Watanabe, Masahiko, Lujan, Rafael, Malenka, Robert C., Striessnig, Joerg, Liss, Birgit
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107734/
https://www.ncbi.nlm.nih.gov/pubmed/24934288
http://dx.doi.org/10.1093/brain/awu131
_version_ 1782327639964385280
author Dragicevic, Elena
Poetschke, Christina
Duda, Johanna
Schlaudraff, Falk
Lammel, Stephan
Schiemann, Julia
Fauler, Michael
Hetzel, Andrea
Watanabe, Masahiko
Lujan, Rafael
Malenka, Robert C.
Striessnig, Joerg
Liss, Birgit
author_facet Dragicevic, Elena
Poetschke, Christina
Duda, Johanna
Schlaudraff, Falk
Lammel, Stephan
Schiemann, Julia
Fauler, Michael
Hetzel, Andrea
Watanabe, Masahiko
Lujan, Rafael
Malenka, Robert C.
Striessnig, Joerg
Liss, Birgit
author_sort Dragicevic, Elena
collection PubMed
description Dopamine midbrain neurons within the substantia nigra are particularly prone to degeneration in Parkinson’s disease. Their selective loss causes the major motor symptoms of Parkinson’s disease, but the causes for the high vulnerability of SN DA neurons, compared to neighbouring, more resistant ventral tegmental area dopamine neurons, are still unclear. Consequently, there is still no cure available for Parkinson’s disease. Current therapies compensate the progressive loss of dopamine by administering its precursor l-DOPA and/or dopamine D2-receptor agonists. D2-autoreceptors and Ca(v)1.3-containing L-type Ca(2+) channels both contribute to Parkinson’s disease pathology. L-type Ca(2+) channel blockers protect SN DA neurons from degeneration in Parkinson’s disease and its mouse models, and they are in clinical trials for neuroprotective Parkinson’s disease therapy. However, their physiological functions in SN DA neurons remain unclear. D2-autoreceptors tune firing rates and dopamine release of SN DA neurons in a negative feedback loop through activation of G-protein coupled potassium channels (GIRK2, or KCNJ6). Mature SN DA neurons display prominent, non-desensitizing somatodendritic D2-autoreceptor responses that show pronounced desensitization in PARK-gene Parkinson’s disease mouse models. We analysed surviving human SN DA neurons from patients with Parkinson’s disease and from controls, and detected elevated messenger RNA levels of D2-autoreceptors and GIRK2 in Parkinson’s disease. By electrophysiological analysis of postnatal juvenile and adult mouse SN DA neurons in in vitro brain-slices, we observed that D2-autoreceptor desensitization is reduced with postnatal maturation. Furthermore, a transient high-dopamine state in vivo, caused by one injection of either l-DOPA or cocaine, induced adult-like, non-desensitizing D2-autoreceptor responses, selectively in juvenile SN DA neurons, but not ventral tegmental area dopamine neurons. With pharmacological and genetic tools, we identified that the expression of this sensitized D2-autoreceptor phenotype required Ca(v)1.3 L-type Ca(2+) channel activity, internal Ca(2+), and the interaction of the neuronal calcium sensor NCS-1 with D2-autoreceptors. Thus, we identified a first physiological function of Ca(v)1.3 L-type Ca(2+) channels in SN DA neurons for homeostatic modulation of their D2-autoreceptor responses. L-type Ca(2+) channel activity however, was not important for pacemaker activity of mouse SN DA neurons. Furthermore, we detected elevated substantia nigra dopamine messenger RNA levels of NCS-1 (but not Ca(v)1.2 or Ca(v)1.3) after cocaine in mice, as well as in remaining human SN DA neurons in Parkinson’s disease. Thus, our findings provide a novel homeostatic functional link in SN DA neurons between Ca(v)1.3- L-type-Ca(2+) channels and D2-autoreceptor activity, controlled by NCS-1, and indicate that this adaptive signalling network (Ca(v)1.3/NCS-1/D2/GIRK2) is also active in human SN DA neurons, and contributes to Parkinson’s disease pathology. As it is accessible to pharmacological modulation, it provides a novel promising target for tuning substantia nigra dopamine neuron activity, and their vulnerability to degeneration.
format Online
Article
Text
id pubmed-4107734
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-41077342014-07-25 Ca(v)1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons Dragicevic, Elena Poetschke, Christina Duda, Johanna Schlaudraff, Falk Lammel, Stephan Schiemann, Julia Fauler, Michael Hetzel, Andrea Watanabe, Masahiko Lujan, Rafael Malenka, Robert C. Striessnig, Joerg Liss, Birgit Brain Original Articles Dopamine midbrain neurons within the substantia nigra are particularly prone to degeneration in Parkinson’s disease. Their selective loss causes the major motor symptoms of Parkinson’s disease, but the causes for the high vulnerability of SN DA neurons, compared to neighbouring, more resistant ventral tegmental area dopamine neurons, are still unclear. Consequently, there is still no cure available for Parkinson’s disease. Current therapies compensate the progressive loss of dopamine by administering its precursor l-DOPA and/or dopamine D2-receptor agonists. D2-autoreceptors and Ca(v)1.3-containing L-type Ca(2+) channels both contribute to Parkinson’s disease pathology. L-type Ca(2+) channel blockers protect SN DA neurons from degeneration in Parkinson’s disease and its mouse models, and they are in clinical trials for neuroprotective Parkinson’s disease therapy. However, their physiological functions in SN DA neurons remain unclear. D2-autoreceptors tune firing rates and dopamine release of SN DA neurons in a negative feedback loop through activation of G-protein coupled potassium channels (GIRK2, or KCNJ6). Mature SN DA neurons display prominent, non-desensitizing somatodendritic D2-autoreceptor responses that show pronounced desensitization in PARK-gene Parkinson’s disease mouse models. We analysed surviving human SN DA neurons from patients with Parkinson’s disease and from controls, and detected elevated messenger RNA levels of D2-autoreceptors and GIRK2 in Parkinson’s disease. By electrophysiological analysis of postnatal juvenile and adult mouse SN DA neurons in in vitro brain-slices, we observed that D2-autoreceptor desensitization is reduced with postnatal maturation. Furthermore, a transient high-dopamine state in vivo, caused by one injection of either l-DOPA or cocaine, induced adult-like, non-desensitizing D2-autoreceptor responses, selectively in juvenile SN DA neurons, but not ventral tegmental area dopamine neurons. With pharmacological and genetic tools, we identified that the expression of this sensitized D2-autoreceptor phenotype required Ca(v)1.3 L-type Ca(2+) channel activity, internal Ca(2+), and the interaction of the neuronal calcium sensor NCS-1 with D2-autoreceptors. Thus, we identified a first physiological function of Ca(v)1.3 L-type Ca(2+) channels in SN DA neurons for homeostatic modulation of their D2-autoreceptor responses. L-type Ca(2+) channel activity however, was not important for pacemaker activity of mouse SN DA neurons. Furthermore, we detected elevated substantia nigra dopamine messenger RNA levels of NCS-1 (but not Ca(v)1.2 or Ca(v)1.3) after cocaine in mice, as well as in remaining human SN DA neurons in Parkinson’s disease. Thus, our findings provide a novel homeostatic functional link in SN DA neurons between Ca(v)1.3- L-type-Ca(2+) channels and D2-autoreceptor activity, controlled by NCS-1, and indicate that this adaptive signalling network (Ca(v)1.3/NCS-1/D2/GIRK2) is also active in human SN DA neurons, and contributes to Parkinson’s disease pathology. As it is accessible to pharmacological modulation, it provides a novel promising target for tuning substantia nigra dopamine neuron activity, and their vulnerability to degeneration. Oxford University Press 2014-08 2014-06-16 /pmc/articles/PMC4107734/ /pubmed/24934288 http://dx.doi.org/10.1093/brain/awu131 Text en © The Author (2014). Published by Oxford University Press on behalf of the Guarantors of Brain. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/),which permits non-commercial reuse, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Original Articles
Dragicevic, Elena
Poetschke, Christina
Duda, Johanna
Schlaudraff, Falk
Lammel, Stephan
Schiemann, Julia
Fauler, Michael
Hetzel, Andrea
Watanabe, Masahiko
Lujan, Rafael
Malenka, Robert C.
Striessnig, Joerg
Liss, Birgit
Ca(v)1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
title Ca(v)1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
title_full Ca(v)1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
title_fullStr Ca(v)1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
title_full_unstemmed Ca(v)1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
title_short Ca(v)1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons
title_sort ca(v)1.3 channels control d2-autoreceptor responses via ncs-1 in substantia nigra dopamine neurons
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4107734/
https://www.ncbi.nlm.nih.gov/pubmed/24934288
http://dx.doi.org/10.1093/brain/awu131
work_keys_str_mv AT dragicevicelena cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT poetschkechristina cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT dudajohanna cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT schlaudrafffalk cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT lammelstephan cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT schiemannjulia cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT faulermichael cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT hetzelandrea cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT watanabemasahiko cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT lujanrafael cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT malenkarobertc cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT striessnigjoerg cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons
AT lissbirgit cav13channelscontrold2autoreceptorresponsesviancs1insubstantianigradopamineneurons